Pharmaceutical investment will not allow pharmaceutical companies to invest in "flooding"

First, the selected products are not competitive, so that the investment funds of enterprises can be used as follows: The product is the base of the pyramid. If the quality of the product itself is not too hard, or the product does not have a high technological content, there is no new perspective, selling point and selling point. To attract consumers, then even when investing in medicine, even if the investment is big and packaging is better, it will be difficult to attract the attention of dealers. There is no shortage of gold in the pharmaceutical investment market. The key is what criteria you use to select and use what form the competitiveness of the product. This is important, but it is really difficult.

Second, the policy formulation is irrational, so that the product is aborted in a half way: Pharmaceutical investment should be built on a mutually beneficial and win-win model. However, the current status quo is that many domestic pharmaceutical investment enterprises generally have the mentality of quick success and instant benefit in pharmaceutical investment. They consider the interests of the manufacturers too much, put the collaborators aside, and only want to use the dealer's network in the early stage of market development. From the perspective of the dealer, the success rate of investment promotion can be imagined.

On the other hand, after a good product's R&D, Haoyisheng Pharmaceutical decided to invest in CCTV, and took the lead in the industry to propose a nanny-style co-sales policy. Family, as a benefit-sharing partner.

The success rate of investment in Chinese companies' medicine is only 2%. Although there are many factors that determine the success or failure of pharmaceutical investment enterprises, products and policies are the cornerstones. Both are necessary conditions for companies to enter the ranks of 2% winners. This is achieved, not far from success.

Third, ignore the high starting point, high-tech, high-quality: Take the case of "Yan Yakang" as an example. Upon the advent of “Ya Yakang”, it actively declared new drugs at the national level, entered Category A OTC and medical insurance, and strived to raise the starting point of products, surpassed similar products in one fell swoop, and became the leader of a new generation of analgesics. Taking into account the patient's affordability, pharmaceutical investment promotion companies reduced the price of the product by developing small packages of various specifications and by expanding the scale of production. Making consumers affordable and allowing consumers to reduce waste based on the course of treatment is the downside.